Qvanteq AG completed a financing round. It provides the company with sufficient cash to further develop its technology for vascular stents such as intracranial stents and flow diverters.
In vivo data involving Qvanteq’s surface technology was published in the April issue of the journal Eurointervention.
Qvanteq AG today announced that its QUEST I study was completed. The technology has shown safety in humans.
The topic of this 18 month program is the “Investigation of in vitro response of human blood to Qvanteq’s anti-thrombotic and pro-healing surface technology applied on vascular stents”.
Qvanteq AG today announced that it completed enrollment of QUEST I study patients.